A Phase 2 Study To Evaluate The Efficacy And Safety Of MK-1026 In Participants With Hematologic Malignancies Read more
“Retrospective Review Of Outcomes And Prognostic Factors Of Patients With COVID-19 Infection And Lymphoid Malignancy” Read more
An Open-Label Study To Assess The Anti-Tumor Activity And Safety Of Regn1979, An Anti-Cd20 X Anti-Cd3 Bispecific Antibody, In Patients With Relapsed Or Refractory Follicular Lymphoma Read more
A Phase 2 Study To Assess The Safety And Efficacy Of TGR-1202 In Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant To Prior BTK (Bruton Tyrosine Kinase) Or PI3K-Delta (Phosphoinositide-3-Kinase) Inhibitor Therapy Read more
A Phase 2 Study To Assess The Efficacy And Safety Of TGR-1202 (Umbralisib) Monotherapy In Patients With Non-Follicular Indolent Non-Hodgkin?S Lymphoma Read more
A Phase 2 Study To Assess The Efficacy And Safety Of Ublituximab And Umbralisib In Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib Or Venetoclax Read more
A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies Read more
A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma Read more
An Open-Label, Dose Escalation And Dose Expansion Trial Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Orally Administered CA-4948 In Patients With Relapsed Or Refractory Hematologic Malignancies Read more
